secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2025-08-01T23:59:59+00:00
Accession:  0001104659-25-072805
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents highlights new sepsis studies showing improved survival with early, intensive CytoSorb use
--------------------------------------------------------------------------------

- Meta-analysis of 744 septic shock patients: CytoSorb reduced in-hospital mortality (OR 0.64, p=0.036) and halved 28–30 day mortality (OR 0.46, p=0.003).
- Berlot et al. study of 175 patients: early intensive CytoSorb use (≥3 cartridges in 2–3 days) nearly doubled survival (70% observed vs 37% predicted).
- 100-patient U.S. COVID-19 registry on ECMO: 74% 90-day survival, rising to 82% with early treatment, outperforming ~50% benchmarks.
- Company to host World Sepsis Day Global Webinar on September 10, 2025 to discuss CytoSorb best practices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925072805/0001104659-25-072805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925072805/tm2522255d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-072805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer